Early sales for Qsymia disappointed investors last week, but Vivus Inc. said the obesity drug's launch reflects the realities of creating a market.

The company said it anticipated those realities and expects sales to pick up over the next six months as physicians begin to see Qsymia's efficacy and as the biotech brings payers on board and rolls out a program to offset out-of-pocket costs.